Familial hypercholesterolaemia

Imagem de Miniatura
Arquivos
art_DEFESCHE_Familial_hypercholesterolaemia_2017.PDF (4.44 MB)
Citações na Scopus
295
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
DEFESCHE, Joep C.
GIDDING, Samuel S.
HARADA-SHIBA, Mariko
HEGELE, Robert A.
WIERZBICKI, Anthony S.
Citação
NATURE REVIEWS DISEASE PRIMERS, v.3, article ID 17093, 20p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Familial hypercholesterolaemia is a common inherited disorder characterized by abnormally elevated serum levels of low-density lipoprotein (LDL) cholesterol from birth, which in time can lead to cardiovascular disease CVD). Most cases are caused by autosomal dominant mutations in LDLR, which encodes the LDL receptor, although mutations in other genes coding for proteins involved in cholesterol metabolism or LDLR function and processing, such as APOB and PCSK9, can also be causative, although less frequently. Several sets of diagnostic criteria for familial hypercholesterolaemia are available; common diagnostic features are an elevated LDL cholesterol level and a family history of hypercholesterolaemia or (premature) CVD. DNA-based methods to identify the underlying genetic defect are desirable but not essential for diagnosis. Cascade screening can contribute to early diagnosis of the disease in family members of an affected individual, which is crucial because familial hypercholesterolaemia can be asymptomatic for decades. Clinical severity depends on the nature of the gene that harbours the causative mutation, among other factors, and is further modulated by the type of mutation. Lifelong LDL cholesterol-lowering treatment substantially improves CVD-free survival and longevity. Statins are the first-line therapy, but additional drugs, such as ezetimibe, bile acid sequestrants, PCSK9 inhibitors and other emerging therapies, are often required.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/25508
Referências
  1. Aatre RD, 2011, CIRC-CARDIOVASC GENE, V4, P81, DOI 10.1161/CIRCGENETICS.110.957365
  2. Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161
  3. Ademi Z, 2014, J CLIN LIPIDOL, V8, P390, DOI 10.1016/j.jacl.2014.05.008
  4. Agard A, 2005, PATIENT EDUC COUNS, V57, P162, DOI 10.1016/j.pec.2004.05.010
  5. Alfonsi JE, 2016, CURR ATHEROSCLER REP, V18, DOI 10.1007/s11883-016-0573-6
  6. Amundsen AL, 2006, ATHEROSCLEROSIS, V189, P451, DOI 10.1016/j.atherosclerosis.2006.01.002
  7. Andersen LH, 2016, J CLIN LIPIDOL, V10, P1297, DOI 10.1016/j.jacl.2016.09.009
  8. Andersen R, 2016, J CLIN LIPIDOL, V10, P225, DOI 10.1016/j.jacl.2015.12.019
  9. ANDERSON RGW, 1976, P NATL ACAD SCI USA, V73, P2434, DOI 10.1073/pnas.73.7.2434
  10. Awan Z, 2013, ATHEROSCLEROSIS, V231, P218, DOI 10.1016/j.atherosclerosis.2013.09.007
  11. Bell DA, 2015, ATHEROSCLEROSIS, V239, P93, DOI 10.1016/j.atherosclerosis.2014.12.036
  12. Benn M, 2012, J CLIN ENDOCR METAB, V97, P3956, DOI 10.1210/jc.2012-1563
  13. Besseling J, 2016, J AM COLL CARDIOL, V68, P252, DOI 10.1016/j.jacc.2016.04.054
  14. Besseling J, 2015, JAMA-J AM MED ASSOC, V313, P1029, DOI 10.1001/jama.2015.1206
  15. Blom DJ, 2017, CIRCULATION, V136, P332, DOI 10.1161/CIRCULATIONAHA.117.028208
  16. Bourbon M, 2017, CURR OPIN LIPIDOL, V28, P120, DOI 10.1097/MOL.0000000000000404
  17. Brahm AJ, 2016, CURR OPIN LIPIDOL, V27, P131, DOI 10.1097/MOL.0000000000000270
  18. BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311
  19. BROWN MS, 1974, SCIENCE, V185, P61, DOI 10.1126/science.185.4145.61
  20. Cannon CP, 2015, NEW ENGL J MED, V372, P2387, DOI 10.1056/NEJMoa1410489
  21. Claassen L, 2012, PSYCHOL HEALTH MED, V17, P511, DOI 10.1080/13548506.2011.644246
  22. Cuchel M, 2014, EUR HEART J, V35, P2146, DOI 10.1093/eurheartj/ehu274
  23. Cuchel M, 2013, LANCET, V381, P40, DOI 10.1016/S0140-6736(12)61731-0
  24. Cupido AJ, 2017, CURR OPIN LIPIDOL, V28, P367, DOI 10.1097/MOL.0000000000000428
  25. Daniels SR, 2011, J CLIN LIPIDOL, V5, pS30, DOI 10.1016/j.jacl.2011.03.453
  26. De Backer G, 2015, ATHEROSCLEROSIS, V241, P169, DOI 10.1016/j.atherosclerosis.2015.04.809
  27. deGoma EM, 2016, CIRC-CARDIOVASC GENE, V9, P240, DOI 10.1161/CIRCGENETICS.116.001381
  28. Dequeker J, 2004, ISRAEL MED ASSOC J, V6, P505
  29. DERKALOUSTIAN VM, 1980, AM J MED GENET, V7, P187, DOI 10.1002/ajmg.1320070212
  30. Do R, 2015, NATURE, V518, P102, DOI 10.1038/nature13917
  31. Eapen DJ, 2012, J CLIN LIPIDOL, V6, P88, DOI 10.1016/j.jacl.2011.08.005
  32. ENDO A, 1976, J ANTIBIOT, V29, P1346, DOI 10.7164/antibiotics.29.1346
  33. ERKELENS DW, 1989, JAMA-J AM MED ASSOC, V262, P2092
  34. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, 2011, Pediatrics, V128 Suppl 5, pS213, DOI 10.1542/peds.2009-2107C
  35. Fagge C. H., 1873, T PATHOL SOC LOND, V24, P242
  36. Fellin R, 2015, GENE, V555, P23, DOI 10.1016/j.gene.2014.09.020
  37. Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144
  38. Fouchier SW, 2014, CIRC RES, V115, P552, DOI 10.1161/CIRCRESAHA.115.304660
  39. Fouchier SW, 2013, CURR OPIN LIPIDOL, V24, P332, DOI 10.1097/MOL.0b013e328361f6c6
  40. Frich JC, 2006, ANN FAM MED, V4, P198, DOI 10.1370/afm.529
  41. Futema M, 2015, CLIN CHEM, V61, P231, DOI 10.1373/clinchem.2014.231365
  42. Gagne C, 2002, CIRCULATION, V105, P2469, DOI 10.1161/01.CIR.0000018744.58460.62
  43. Galabova G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114469
  44. Genest J, 2014, CAN J CARDIOL, V30, P1471, DOI 10.1016/j.cjca.2014.09.028
  45. Gidding SS, 2015, CIRCULATION, V132, P2167, DOI 10.1161/CIR.0000000000000297
  46. GOLDSTEIN JL, 1973, P NATL ACAD SCI USA, V70, P2804, DOI 10.1073/pnas.70.10.2804
  47. Goldstein JL, 2001, METABOLIC MOL BASES, VII, P2863
  48. Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564
  49. Graesdal A, 2012, J CLIN LIPIDOL, V6, P331, DOI 10.1016/j.jacl.2012.03.004
  50. Gryn SE, 2016, CURR OPIN LIPIDOL, V27, P579, DOI 10.1097/MOL.0000000000000354
  51. Haralambos K, 2015, ATHEROSCLEROSIS, V240, P190, DOI 10.1016/j.atherosclerosis.2015.03.003
  52. Hegele RA, 2015, ARTERIOSCL THROM VAS, V35, P2269, DOI 10.1161/ATVBAHA.115.306442
  53. Hegele RA, 2015, CURR OPIN LIPIDOL, V26, P103, DOI 10.1097/MOL.0000000000000163
  54. Hegele RA, 2009, NAT REV GENET, V10, P109, DOI 10.1038/nrg2481
  55. Homsma SJM, 2008, EUR J HUM GENET, V16, P14, DOI 10.1038/sj.ejhg.5201940
  56. Hopkins PN, 2015, CIRC-CARDIOVASC GENE, V8, P823, DOI 10.1161/CIRCGENETICS.115.001129
  57. Huijgen R, 2012, EUR J HUM GENET, V20, P722, DOI 10.1038/ejhg.2012.5
  58. Huijgen R, 2011, CIRC-CARDIOVASC GENE, V4, P413, DOI 10.1161/CIRCGENETICS.110.959239
  59. Huijgen R, 2010, CLIN THER, V32, P615, DOI 10.1016/j.clinthera.2010.04.014
  60. Iacocca MA, 2017, EXPERT REV MOL DIAGN, V17, P641, DOI 10.1080/14737159.2017.1332997
  61. Ito MK, 2011, J CLIN LIPIDOL, V5, pS38, DOI 10.1016/j.jacl.2011.04.001
  62. Jansen ACM, 2002, CURR OPIN LIPIDOL, V13, P165, DOI 10.1097/00041433-200204000-00008
  63. Kassim SH, 2013, HUM GENE THER, V24, P19, DOI 10.1089/hum.2012.108
  64. Kastelein JJP, 2008, NEW ENGL J MED, V358, P1431, DOI 10.1056/NEJMoa0800742
  65. Kastelein JJP, 2017, J CLIN LIPIDOL, V11, P195, DOI 10.1016/j.jacl.2016.12.004
  66. KHACHADURIAN AK, 1964, AM J MED, V37, P402, DOI 10.1016/0002-9343(64)90196-2
  67. Khera AV, 2016, J AM COLL CARDIOL, V67, P2578, DOI 10.1016/j.jacc.2016.03.520
  68. Klancar G, 2015, J AM COLL CARDIOL, V66, P1250, DOI 10.1016/j.jacc.2015.07.017
  69. Kusters DM, 2012, ARCH DIS CHILD, V97, P272, DOI 10.1136/archdischild-2011-300081
  70. Landmesser U, 2017, EUR HEART J, V38, P2245, DOI 10.1093/eurheartj/ehw480
  71. Langsted A, 2016, LANCET DIABETES ENDO, V4, P577, DOI 10.1016/S2213-8587(16)30042-0
  72. Lansberg P J, 2000, Ned Tijdschr Geneeskd, V144, P1437
  73. Liyanage KE, 2011, CRIT REV CL LAB SCI, V48, P1, DOI 10.3109/10408363.2011.565585
  74. Lozano P, 2016, JAMA-J AM MED ASSOC, V316, P645, DOI 10.1001/jama.2016.6176
  75. Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
  76. Lyceum CME Inc, 2013, PATIENT MONITORING S
  77. MAHER VMG, 1995, JAMA-J AM MED ASSOC, V274, P1771, DOI 10.1001/jama.274.22.1771
  78. Mancini GBJ, 2013, CAN J CARDIOL, V29, P1553, DOI 10.1016/j.cjca.2013.09.023
  79. Marais Adrian David, 2004, Semin Vasc Med, V4, P93
  80. Marks D, 2003, ATHEROSCLEROSIS, V168, P1, DOI 10.1016/S0021-9150(02)00330-1
  81. Miller PE, 2015, J CLIN LIPIDOL, V9, P676, DOI 10.1016/j.jacl.2015.06.015
  82. Moore KJ, 2005, J CLIN INVEST, V115, P2192, DOI 10.1172/JCI24061
  83. MOORJANI S, 1989, ARTERIOSCLEROSIS, V9, P211, DOI 10.1161/01.ATV.9.2.211
  84. MOORJANI S, 1993, LANCET, V341, P1303, DOI 10.1016/0140-6736(93)90815-X
  85. MOUTAFIS CD, 1977, ATHEROSCLEROSIS, V26, P329, DOI 10.1016/0021-9150(77)90085-5
  86. Muller C, 1938, ACTA MED SCAND, P75
  87. Nanchen D, 2016, CIRCULATION, V134, P698, DOI 10.1161/CIRCULATIONAHA.116.023007
  88. National Institute for Health and Care Excellence, 2016, EZ TREAT PRIM HET FA
  89. Nherera L, 2011, HEART, V97, P1175, DOI 10.1136/hrt.2010.213975
  90. Nordestgaard BG, 2017, EUR HEART J, V38, P1580, DOI 10.1093/eurheartj/ehx136
  91. Nordestgaard BG, 2013, EUR HEART J, V34, P3478, DOI 10.1093/eurheartj/eht273
  92. Orringer CE, 2017, J CLIN LIPIDOL, V11, P880, DOI [10.1016/j.jacl.2017.05.001, 10.1016/j.jac1.2017.05.001]
  93. Ose L, 2008, CURR CARDIOL REV, V4, P60, DOI 10.2174/157340308783565401
  94. Paquette M, 2017, J CLIN LIPIDOL, V11, P1161, DOI 10.1016/j.jacl.2017.07.008
  95. Paquette M, 2017, J CLIN LIPIDOL, V11, P80, DOI 10.1016/j.jacl.2016.10.004
  96. Patel SB, 2014, CURR OPIN LIPIDOL, V25, P169, DOI 10.1097/MOL.0000000000000071
  97. Perak AM, 2016, CIRCULATION, V134, P9, DOI 10.1161/CIRCULATIONAHA.116.022335
  98. de Isla LP, 2017, CIRCULATION, V135, P2133, DOI 10.1161/CIRCULATIONAHA.116.024541
  99. de Isla LP, 2016, ARTERIOSCL THROM VAS, V36, P2004, DOI 10.1161/ATVBAHA.116.307514
  100. Qian L. J., 2017, SCI REP, V7, P238
  101. Raal FJ, 2017, LANCET DIABETES ENDO, V5, P280, DOI 10.1016/S2213-8587(17)30044-X
  102. Raal FJ, 2015, LANCET, V385, P331, DOI 10.1016/S0140-6736(14)61399-4
  103. Raal FJ, 2015, LANCET, V385, P341, DOI 10.1016/S0140-6736(14)61374-X
  104. Raal FJ, 2012, ATHEROSCLEROSIS, V223, P262, DOI 10.1016/j.atherosclerosis.2012.02.019
  105. Raal FJ, 2011, CIRCULATION, V124, P2202, DOI 10.1161/CIRCULATIONAHA.111.042523
  106. Raal FJ, 2010, LANCET, V375, P998, DOI 10.1016/S0140-6736(10)60284-X
  107. Ray KK, 2017, NEW ENGL J MED, V376, P1430, DOI 10.1056/NEJMoa1615758
  108. Ridker PM, 2017, NEW ENGL J MED, V376, P1527, DOI 10.1056/NEJMoa1701488
  109. Rios J, 2010, HUM MOL GENET, V19, P4313, DOI 10.1093/hmg/ddq352
  110. Robinson JG, 2016, J AM COLL CARDIOL, V68, P2412, DOI 10.1016/j.jacc.2016.09.928
  111. Robinson JG, 2011, J CLIN LIPIDOL, V5, pS18, DOI 10.1016/j.jacl.2011.03.451
  112. Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI 10.1056/NEJMoa1615664
  113. Santos RD, 2017, CURR OPIN LIPIDOL, V28, P130, DOI 10.1097/MOL.0000000000000391
  114. Santos RD, 2016, LANCET DIABETES ENDO, V4, P850, DOI 10.1016/S2213-8587(16)30041-9
  115. Santos RD, 2016, LANCET DIABETES ENDO, V4, P553, DOI 10.1016/S2213-8587(16)30082-1
  116. Santos RD, 2015, J ATHEROSCLER THROMB, V22, P869, DOI 10.5551/jat.31237
  117. Santos RD, 2014, CURR OPIN LIPIDOL, V25, P183, DOI 10.1097/MOL.0000000000000073
  118. Sbrana F, 2017, EUR J PREV CARDIOL, V24, P1528, DOI 10.1177/2047487317712419
  119. Schonewille M, 2016, CURR OPIN LIPIDOL, V27, P295, DOI 10.1097/MOL.0000000000000303
  120. Scientific Steering Committee on behalf of the Simon Broome Register Group, 1991, BMJ-BRIT MED J, V303, P893
  121. Shi ZM, 2014, INT J CARDIOL, V174, P834, DOI 10.1016/j.ijcard.2014.04.165
  122. Sjouke B, 2015, EUR HEART J, V36, P560, DOI 10.1093/eurheartj/ehu058
  123. Smilde TJ, 2001, LANCET, V357, P577, DOI 10.1016/S0140-6736(00)04053-8
  124. SMIT JWA, 1995, EUR J CLIN INVEST, V25, P79, DOI 10.1111/j.1365-2362.1995.tb01530.x
  125. Somanathan S, 2014, CIRC RES, V115, P591, DOI 10.1161/CIRCRESAHA.115.304008
  126. Stein EA, 2017, J AM COLL CARDIOL, V70, P1162, DOI 10.1016/j.jacc.2017.06.058
  127. Steyn K, 1996, HUM GENET, V98, P479, DOI 10.1007/s004390050243
  128. Stitziel NO, 2013, ARTERIOSCL THROM VAS, V33, P2909, DOI 10.1161/ATVBAHA.113.302426
  129. Stroes ES, 2015, EUR HEART J, V36, P1012, DOI 10.1093/eurheartj/ehv043
  130. STROES ESG, 1995, LANCET, V346, P467, DOI 10.1016/S0140-6736(95)91322-X
  131. Sturm AC, 2016, FRONT CARDIOVASC MED, V3, DOI 10.3389/fcvm.2016.00011
  132. Talmud PJ, 2013, LANCET, V381, P1293, DOI 10.1016/S0140-6736(12)62127-8
  133. The HPS3-TIMI55-REVEAL Collaborative Group, 2017, NEW ENGL J MED, V377, P1217
  134. Thompson GR, 2013, ATHEROSCLEROSIS SUPP, V14, P67, DOI 10.1016/j.atherosclerosissup.2012.10.001
  135. THOMPSON GR, 1995, CAN J CARDIOL, V345, P811
  136. Tonstad S, 1996, J PEDIATR-US, V129, P42, DOI 10.1016/S0022-3476(96)70188-9
  137. Turner T, 2015, CLIN THER, V37, P2751, DOI 10.1016/j.clinthera.2015.09.004
  138. Umans-Eckenhausen MAW, 2001, LANCET, V357, P165, DOI 10.1016/S0140-6736(00)03587-X
  139. Vallejo-Vaz AJ, 2016, ATHEROSCLEROSIS SUPP, V22, P1, DOI 10.1016/j.atherosclerosissup.2016.10.001
  140. van der Graaf A, 2008, ANN INTERN MED, V148, P712, DOI 10.7326/0003-4819-148-9-200805060-00022
  141. Varvel S. A., 2015, J CLIN LIPIDOL, V9, P103
  142. Versmissen J, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2423
  143. WALD DS, 2016, ENGL J MED, V375, P1628, DOI 10.1056/NEJMOA1602777
  144. Wang A, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003294
  145. Wang J, 2005, J LIPID RES, V46, P366, DOI 10.1194/jlr.D400030-JLR200
  146. Wang J, 2016, ARTERIOSCL THROM VAS, V36, P2439, DOI 10.1161/ATVBAHA.116.308027
  147. Wang LDR, 2017, CAN J CARDIOL, V33, P334, DOI [10.1016/j.cjca.2016.11.003, 10.1016/j.cjca.2016.1.003]
  148. Watts GF, 2015, INT J CARDIOL, V185, P69, DOI 10.1016/j.ijcard.2015.03.027
  149. Watts GF, 2014, INT J CARDIOL, V171, P309, DOI 10.1016/j.ijcard.2013.11.025
  150. Weng SF, 2015, ATHEROSCLEROSIS, V238, P336, DOI 10.1016/j.atherosclerosis.2014.12.034
  151. Wiegman A, 2015, EUR HEART J, V36, P2425, DOI 10.1093/eurheartj/ehv157
  152. Wierzbicki AS, 2016, CLIN MED, V16, P353, DOI 10.7861/clinmedicine.16-4-353
  153. Wierzbicki AS, 2015, CURR OPIN LIPIDOL, V26, P475, DOI 10.1097/MOL.0000000000000238
  154. Wierzbicki AS, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1095
  155. WILKINSON CF, 1948, ANN INTERN MED, V29, P671, DOI 10.7326/0003-4819-29-4-671
  156. Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797
  157. WILLIAMS RR, 1993, AM J CARDIOL, V72, P171, DOI 10.1016/0002-9149(93)90155-6
  158. Wittekoek ME, 1998, CIRCULATION, V97, P729

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - ODS/03